Treatment options for relapsed and refractory multiple myeloma

Clinical Cancer Research

Volumn 17, Issue 6, 2011, Pages 1264-1277

  Lonial, Sagar ^a   Mitsiades, Constantine S ^b   Richardson, Paul G ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BEVACIZUMAB; BORTEZOMIB; CARFILZOMIB; CARMUSTINE; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ELOTUZUMAB; ENOXAPARIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN 90 INHIBITOR; HLA ANTIGEN; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MELPHALAN; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PANOBINOSTAT; PERIFOSINE; PREDNISONE; ROMIDEPSIN; SALINOSPORAMIDE A; TANESPIMYCIN; TEMSIROLIMUS; THALIDOMIDE; UNINDEXED DRUG; VINCRISTINE; VORINOSTAT; WARFARIN;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG TARGETING; FATIGUE; GASTROINTESTINAL DISEASE; GRAFT VERSUS HOST REACTION; HLA MATCHING; HUMAN; LYMPHOCYTOPENIA; MEDICAL DECISION MAKING; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; TERATOGENICITY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; CLINICAL TRIALS AS TOPIC; DEXAMETHASONE; DRUG RESISTANCE, NEOPLASM; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; MULTIPLE MYELOMA; PYRAZINES; RECURRENCE; REMISSION INDUCTION; THALIDOMIDE;

EID: 79952720734     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-1805     Document Type: Review

References (142)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med 2004; 351:1860-73.
2. Harousseau JL, Shaughnessy J Jr, Richardson P. Multiple myeloma. Hematology Am Soc Hematol Educ Program 2004:237-56.
3. Podar K, Tai YT, Hideshima T, Vallet S, Richardson PG, Anderson KC. Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs 2009;14:99-127.
4. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104:607-18. (Pubitemid 38970551)
5. Anderson KC. Oncogenomics to target myeloma in the bone marrow microenvironment. Clin Cancer Res 2011;17:1225-33.
6. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004;127:165-72. (Pubitemid 39371809)
7. Richardson PG, Mitsiades C, Schlossman R, Munshi N, Anderson K. New drugs for myeloma. Oncologist 2007;12:664-89. (Pubitemid 47036203)
8. Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: New diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17:1243-52.
9. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol 2005;23:3412-20.
10. Rajkumar S, Fonseca R, Lacy M, Witzig T, Lust J, Greipp P, et al. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma. Bone Marrow Transplant 1999;24:497-503. (Pubitemid 29423628)
11. Gutievrrez NC, Castellanos MV, Martín ML, Mateos MV, Hernández JM, Fernández M, et al. GEM/PETHEMA Spanish Group. Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated with adverse prognosis. Leukemia 2007;21:143-50.
12. Avet-Loiseau H. Role of genetics in prognostication in myeloma. Best Pract Res Clin Haematol 2007;20:625-35. (Pubitemid 350225352)
13. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, et al. The molecular classification of multiple myeloma. Blood 2006;108:2020-8. (Pubitemid 44395016)
14. Munshi N, Avet-Loiseau H. Genomics in multiple myeloma. Clin Cancer Res 2011;17:1234-42.
15. Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G, et al. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Br J Haematol 1998;102:1115-23. (Pubitemid 28435189)
16. Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, et al. International Myeloma Working Group. International uniform response criteria formultiple myeloma. Leukemia 2006;20:1467-73.
17. Anderson KC, Kyle RA, Rajkumar SV, Stewart AK, Weber D, Richardson PASH/FDA Panel on Clinical Endpoints in Multiple Myeloma. Clinically relevant end points and new drug approvals for myeloma. Leukemia 2008;22:231-9.
18. Alexanian R, Barlogie B, Dixon D. High-dose glucocorticoid treatment of resistant myeloma. Ann Intern Med 1986;105:8-11. (Pubitemid 16097913)
19. Gertz MA, Garton JP, Greipp PR, Witzig TE, Kyle RA. A phase II study of high-dose methylprednisolone in refractory or relapsed multiple myeloma. Leukemia 1995;9:2115-8. (Pubitemid 26023798)
20. Barlogie B, Smith L, Alexanian R. Effective treatment of advanced multiple myeloma refractory to alkylating agents. N Engl J Med 1984;310:1353-6. (Pubitemid 14149087)
21. Anderson H, Scarffe JH, Ranson M, Young R, Wieringa GS, Morgenstern GR, et al. VAD chemotherapy as remission induction for multiple myeloma. Br J Cancer 1995;71:326-30.
22. Gertz MA, Kalish LA, Kyle RA, Hahn RG, Tormey DC, Oken MM. Phase III study comparing vincristine, doxorubicin (Adriamycin), and dexamethasone (VAD) chemotherapy with VAD plus recombinant interferon alfa-2 in refractory or relapsed multiple myeloma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1995;18:475-80. (Pubitemid 26004052)
23. Lokhorst HM, Meuwissen OJ, Bast EJ, Dekker AW. VAD chemotherapy for refractory multiple myeloma. Br J Haematol 1989;71:25-30. (Pubitemid 19047692)
24. Phillips JK, Sherlaw-Johnson C, Pearce R, Davies JM, Reilly JT, Newland AC, et al. A randomized study of MOD versus VAD in the treatment of relapsed and resistant multiple myeloma. Leuk Lymphoma 1995;17:465-72.
25. Durie BG, Dixon DO, Carter S, Stephens R, Rivkin S, Bonnet J, et al. Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study. J Clin Oncol 1986;4:1227-37. (Pubitemid 16043874)
26. Giles FJ, Wickham NR, Rapoport BL, Somlo G, Lim SW, Shan J, et al. Cyclophosphamide, etoposide, vincristine, adriamycin, and dexamethasone (CEVAD) regimen in refractory multiple myeloma: an International Oncology Study Group (IOSG) phase II protocol. Am J Hematol 2000;63:125-30. (Pubitemid 30120765)
27. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma. Lancet 1983;2:822-4. (Pubitemid 13013370)
28. Barlogie B, Alexanian R, Dicke KA, Zagars G, Spitzer G, Jagannath S, et al. High-dose chemoradiotherapy and autologous bone marrow transplantation for resistant multiple myeloma. Blood 1987;70:869-72. (Pubitemid 18027425)
29. Barlogie B, Hall R, Zander A, Dicke K, Alexanian R. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986;67:1298-301. (Pubitemid 16080597)
30. Burzynski JA, Toro JJ, Patel RC, Lee S, Greene RE, Ochoa-Bayona JL, et al. Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma. Leuk Lymphoma 2009;50:1442-7.
31. Elice F, Raimondi R, Tosetto A, D'Emilio A, Di Bona E, Piccin A, et al. Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006;81:426-31. (Pubitemid 43787930)
32. Krivanová A, Hájek R, Krejcí M, Scudla V, Indr-ak K, Bacovský J, et al. Czech Myeloma Group. Second autologous transplantation for multiple myeloma patients relapsing after the first autograft - a pilot study for the evaluation of experimental maintenance therapies. Report of the prospective non-randomized pilot study of the Czech Myeloma Group. Onkologie 2004;27:275-9.
33. Olin RL, Vogl DT, Porter DL, Luger SM, Schuster SJ, Tsai DE, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-22.
34. Qazilbash MH, Saliba R, De Lima M, Hosing C, Couriel D, Aleman A, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084-9.
35. Alvares CL, Davies FE, Horton C, Patel G, Powles R, Morgan GJ. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141-2. (Pubitemid 43235400)
36. Gahrton G, Tura S, Ljungman P, Bladé J, Brandt L, Cavo M, et al. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma. J Clin Oncol 1995;13:1312-22.
37. Kr€oger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A, et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004;10:698-708. (Pubitemid 39272874)
38. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I, et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006;107:3474-80.
39. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341:1565-71.
40. Barlogie B, Desikan R, Eddlemon P, Spencer T, Zeldis J, Munshi N, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-4.
41. Glasmacher A, Hahn C, Hoffmann F, Naumann R, Goldschmidt H, von Lilienfeld-Toal M, et al. A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma. Br J Haematol 2006;132:584-93. (Pubitemid 43381591)
42. Mileshkin L, Stark R, Day B, Seymour JF, Zeldis JB, Prince HM. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006;24:4507-14. (Pubitemid 46630990)
43. Richardson P, Schlossman R, Jagannath S, Alsina M, Desikan R, Blood E, et al. Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity. Mayo Clin Proc 2004;79:875-82. (Pubitemid 38879953)
44. Dimopoulos MA, Zervas K, Kouvatseas G, Galani E, Grigoraki V, Kiamouris C, et al. Thalidomide and dexamethasone combination for refractory multiple myeloma. Ann Oncol 2001;12:991-5. (Pubitemid 32725775)
45. Kropff MH, Lang N, Bisping G, Dominé N, Innig G, Hentrich M, et al. Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma. Br J Haematol 2003;122:607-16. (Pubitemid 36995215)
46. Srkalovic G, Elson P, Trebisky B, Karam MA, Hussein MA. Use of melphalan, thalidomide, and dexamethasone in treatment of refractory and relapsed multiple myeloma. Med Oncol 2002;19:219-26. (Pubitemid 36016012)
47. García-Sanz R, González-Porras JR, Hernández JM, Polo-Zarzuela M, Sureda A, Barrenetxea C, et al. The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma. Leukemia 2004;18:856-63. (Pubitemid 38500205)
48. Dimopoulos MA, Hamilos G, Zomas A, Gika D, Efstathiou E, Grigoraki V, et al. Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma. Hematol J 2004;5:112-7. (Pubitemid 38519259)
49. Sidra G, Williams CD, Russell NH, Zaman S, Myers B, Byrne JL. Combination chemotherapy with cyclophosphamide, thalidomide and dexamethasone for patients with refractory, newly diagnosed or relapsed myeloma. Haematologica 2006;91:862-3. (Pubitemid 44014564)
50. Kyriakou C, Thomson K, D'Sa S, Flory A, Hanslip J, Goldstone AH, et al. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma. Br J Haematol 2005;129:763-70. (Pubitemid 40904526)
51. Hovenga S, Daenen SM, de Wolf JT, van Imhoff GW, Kluin-Nelemans HC, Sluiter WJ, et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 2005;84:311-6. (Pubitemid 41166825)
52. Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, et al. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21. Oncologist 2007;12:99-106. (Pubitemid 46143507)
53. Palumbo A, Avonto I, Bruno B, Ambrosini MT, Bringhen S, Cavallo F, et al. Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma. Eur J Haematol 2006;76:273-7. (Pubitemid 43362934)
54. Hussein MA, Baz R, Srkalovic G, Agrawal N, Suppiah R, Hsi E, et al. Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma. Mayo Clin Proc 2006;81:889-95. (Pubitemid 43993480)
55. Offidani M, Corvatta L, Marconi M, Visani G, Alesiani F, Brunori M, et al. Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed/refractory multiple myeloma: a prospective, multicenter, phase II study. Haematologica 2006;91:133-6. (Pubitemid 43235397)
56. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, et al. VTD combination therapy with bortezomib-thalidomide- dexamethasone is highly effective in advanced and refractory multiple myeloma. Leukemia 2008;22:1419-27. (Pubitemid 352006086)
57. Ciolli S, Leoni F, Gigli F, Rigacci L, Bosi A. Low dose Velcade, thalidomide and dexamethasone (LD-VTD): an effective regimen for relapsed and refractory multiple myeloma patients. Leuk Lymphoma 2006;47:171-3. (Pubitemid 43101744)
58. Offidani M, Bringhen S, Corvatta L, Falco P, Marconi M, Avonto I, et al. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma. Eur J Haematol 2007;78:297-302. (Pubitemid 46365087)
59. Eby CS. Bleeding and thrombosis risks in plasma cell dyscrasias. Hematology Am Soc Hematol Educ Program 2007;2007:158-64.
60. Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, et al. International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-23.
61. Palumbo A, Cavo M, Bringhen S, Cavalli M, Patriarca F, Rossi D, et al. A phase III study of enoxaparin vs aspirin vs low-dose warfarin as thromboprophylaxis for newly diagnosed myeloma patients treated with thalidomide based-regimens. Blood (ASH Annual Meeting Abstracts) 2009;114:492-.
62. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348:2609-17. (Pubitemid 36741588)
63. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin DH, et al. Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time-to-event results from the SUMMIT trial. Cancer 2006;106:1316-9. (Pubitemid 43363908)
64. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-98.
65. Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-60.
66. Jagannath S, Richardson PG, Barlogie B, Berenson JR, Singhal S, Irwin D, et al. SUMMIT/CREST Investigators. Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006;91:929-34.
67. Mikhael JR, Belch AR, Prince HM, Lucio MN, Maiolino A, Corso A, et al. High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. Br J Haematol 2009;144:169-75.
68. Kropff MH, Bisping G, Wenning D, Volpert S, Tchinda J, Berdel WE, et al. Bortezomib in combination with dexamethasone for relapsed multiple myeloma. Leuk Res 2005;29:587-90. (Pubitemid 40327248)
69. Lonial S, Waller EK, Richardson PG, Jagannath S, Orlowski RZ, Giver CR, et al. SUMMIT/CREST Investigators. Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005;106:3777-84.
70. Richardson PG, Briemberg H, Jagannath S, Wen PY, Barlogie B, Berenson J, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006;24:3113-20. (Pubitemid 46638949)
71. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, et al. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007;109:2604-6. (Pubitemid 46425908)
72. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, et al. SUMMIT/CREST Investigators. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005;103:1195-200.
73. Lonial S, Richardson PG, San Miguel J, Sonneveld P, Schuster MW, Bladé J, et al. Characterisation of haematological profiles and low risk of thromboembolic events with bortezomib in patients with relapsed multiple myeloma. Br J Haematol 2008;143:222-9.
74. Chanan-khan AA, Padmanabhan S, Miller KC, Musiel L, Yu J, Bernstein ZP, et al. Final results of a phase II study of bortezomib (velcade) in combination with liposomal doxorubicin (doxil) and thalidomide (VDT) demonstrate a sustained high response rates in patients (pts) with relapsed (rel) or refactory (ref) multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2006;108:3539.
75. Jakubowiak AJ, Brackett L, Kendall T, Friedman J, Kaminski MS. Combination therapy with velcade, doxil, and dexamethasone (VDD) for patients with relapsed/refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2005;106:5179.
76. Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, et al. Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin. Ann Hematol 2007;86:211-6. (Pubitemid 46195994)
77. Berenson JR, Yang HH, Sadler K, Jarutirasarn SG, Vescio RA, Mapes R, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol 2006;24:937-44. (Pubitemid 46638848)
78. Popat R, Oakervee HE, Foot N, Agrawal S, Smith P, Craddock C, et al. A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2005;106:2555.
79. Terpos E, Anagnostopoulos A, Kastritis E, Zomas A, Poziopoulos C, Anagnostopoulos N, et al. The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide (VMDT) is an effective treatment for relapsed/refractory myeloma: results of a phase II clinical trial. Blood (ASH Annual Meeting Abstracts) 2005;106:363.
80. Palumbo A, Ambrosini MT, Benevolo G, Pregno P, Pescosta N, Callea V, et al. Italian Multiple Myeloma Network; Gruppo Italiano Malattie Ematologicche dell'Adulto. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. Blood 2007;109:2767-72.
81. Kropff M, Bisping G, Schuck E, Liebisch P, Lang N, Hentrich M, et al. Deutsche Studiengruppe Multiples Myelom. Bortezomib in combination with intermediate-dose dexamethasone and continuous lowdose oral cyclophosphamide for relapsed multiple myeloma. Br J Haematol 2007;138:330-7. (Pubitemid 47035389)
82. Davies FE, Wu P, Srikanth M, Jenner MW, Dines S, Saso R, et al. The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with minimal toxicity compared to velcade alone (V) and velcade plus dexamethasone (VD). Blood (ASH Annual Meeting Abstracts) 2006;108:3537.
83. Reece DE, Piza Rodriguez G, Chen C, Trudel S, Kukreti V, Mikhael J, et al. Phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone in relapsed and refractory multiple myeloma. J Clin Oncol 2008;26:4777-83.
84. Orlowski RZ, Nagler A, Sonneveld P, Bladé J, Hajek R, Spencer A, et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. J Clin Oncol 2007;25:3892-901. (Pubitemid 47477266)
85. Weber D, Knight R, Chen C, Spencer S, Yu Z, Zeldis J, et al. Prolonged overall survival with lenalidomide plus dexamethasone compared with dexamethasone alone in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007;110:412.
86. Dimopoulos M, Spencer A, Attal M, Prince HM, Harousseau JL, Dmoszynska A, et al. Multiple Myeloma (010) Study Investigators. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-32.
87. Nooka AK, Kaufman JL, Heffner LT, Gleason CL, Lonial S. Thromboembolic events (TEE) with lenalidomide-based therapies for multiple myeloma (MM): Emory experience. Blood (ASH Annual Meeting Abstracts) 2009;114:3888.
88. Richardson PG, Blood E, Mitsiades CS, Jagannath S, Zeldenrust SR, Alsina M, , et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006;108:3458-64.
89. Reece DE, Masih-Khan E, Chen C, Wang L, Dean S, Kukreti V, et al. Use of lenalidomide (Revlimid(R) - corticosteroids in relapsed/refractory multiple myeloma patients with elevated baseline serum creatinine levels. Blood (ASH Annual Meeting Abstracts)2006;108:3548.
90. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Greipp P. A randomized phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the eastern cooperative oncology group. Blood (ASH Annual Meeting Abstracts) 2006;108:799.
91. Chen N, Lau H, Kong L, Kumar G, Zeldis JB, Knight R, et al. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis. J Clin Pharmacol 2007;47:1466-75. (Pubitemid 350115306)
92. Baz R, Walker E, Karam MA, Choueiri TK, Jawde RA, Bruening K, et al. Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy. Ann Oncol 2006;17:1766-71. (Pubitemid 44884050)
93. Knop S, Gerecke C, Topp MS, Liebisch P, Hess G, Kotkiewitz S, et al. Lenalidomide (RevlimidTM), adriamycin and dexamethasone chemotherapy (RAD) is safe and effective in treatment of relapsed multiple myeloma - first results of a german multicenter phase I/II trial. Blood (ASH Annual Meeting Abstracts) 2006;108:408.
94. Morgan GJ, Schey SA, Wu P, Srikanth M, Phekoo KJ, Jenner M, et al. Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients. Br J Haematol 2007;137:268-9. (Pubitemid 46537629)
95. Richardson PG, Weller E, Jagannath S, Avigan DE, Alsina M, Schlossman RL, et al. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol 2009;27:5713-9.
96. Anderson K, Jagannath S, Jakubowiak A, Lonial S, Raje N, Alsina M, et al. Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study. J Clin Oncol 2009;27 (suppl): 8536.
97. Richardson P, Laubach JP, Schlossman R, Mitsiades C, Anderson K. Treatment of multiple myeloma patients not eligible for ASCT. 2010 Educational Meeting; 2010 May 6-9; Monte Real, Portugal; Portugese Society of Hematology; 2010.
98. Mikhael JR, Goodwin J, Qi X, Xu W, Stewart K, Reece D, et al. p53 deletion yields high response rates but rapid progression and poor overall survival in multiple myeloma patients undergoing autologous stem cell transplantation. Blood (ASH Annual Meeting Abstracts) 2007;110:953.
99. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Kung AL, Davies FE, et al. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006;107:1092-100. (Pubitemid 43156310)
100. Richardson PG, Chanan-Khan A, Lonial S, Krishman A, Carroll M, Cropp GF, et al. Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood (ASH Annual Meeting Abstracts)2007;110:1165.
101. Neckers L. Heat shock protein 90: the cancer chaperone. J Biosci 2007;32:517-30. (Pubitemid 46708702)
102. Peng C, Li D, Li S. Heat shock protein 90: a potential therapeutic target in leukemic progenitor and stem cells harboring mutant BCR-ABL resistant to kinase inhibitors. Cell Cycle 2007;6:2227-31. (Pubitemid 47547697)
103. Spisek R, Dhodapkar MV. Towards a better way to die with chemotherapy: role of heat shock protein exposure on dying tumor cells. Cell Cycle 2007;6:1962-5. (Pubitemid 47327881)
104. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin Cancer Res 2007;13:1625-9. (Pubitemid 46952925)
105. Catley L, Weisberg E, Kiziltepe T, Tai YT, Hideshima T, Neri P, et al. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood 2006;108:3441-9.
106. David E, Schafer-Hales K, Marcus AI, Kaufman JL, Lonial S. Combination of bortezomib with tipifarnib (R115777) induces synergistic myeloma cell apoptosis via down-regulation of HDAC6 and inhibition of aggresome formation. Blood (ASH Annual Meeting Abstracts) 2007;110:1520.
107. Hideshima T, Bradner JE, Wong J, Chauhan D, Richardson P, Schreiber SL, et al. Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A 2005;102:8567-72. (Pubitemid 40862776)
108. Badros A, Philip S, Niesvizky R, Goloubeva O, Harris C, Zweibel J, et al. Phase I trial of suberoylanilide hydroxamic acid (SAHA) + bortezomib (Bort) in relapsed multiple myeloma (MM) patients (pts). Blood (ASH Annual Meeting Abstracts)2007;110:1168.
109. Weber DM, Jagannath S, Mazumder A, Sobecks R, Schiller GJ, Gavino M, et al. Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with bortezomib in patients with advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2007;110:1172.
110. Prince M, Quach H, Neeson P, Keegan M, Copeman M, Peinert S, et al. Safety and efficacy of the combination of bortezomib with the deacetylase inhibitor romidepsin in patients with relapsed or refractory multiple myeloma: preliminary results of a phase I trial. Blood (ASH Annual Meeting Abstracts) 2007;110:1167.
111. Harvey RD, Lonial S. PI3 kinase/AKT pathway as a therapeutic target in multiple myeloma. Future Oncol 2007;3:639-47.
112. Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, et al. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood 2006;107:4053-62. (Pubitemid 43726814)
113. Richardson P, Lonial S, Jakubowiak A, Krishnan A, Wolf J, Densmore J, et al. Multi-center phase II study of perifosine (KRX-0401) alone and in combination with dexamethasone (dex) for patients with relapsed or relapsed/refractory multiple myeloma (MM): promising activity as combination therapy with manageable toxicity. Blood (ASH Annual Meeting Abstracts) 2007;110:1164.
114. Richardson P, Wolf J, Jakubowiak A, , et al. Phase I/II of a multicenter trial of perifosine (KRX-0401) + bortezomib in relapsed or relapsed/refractory multiple myeloma patients previously relapsed from or refractory to bortezomib. Proceedings of the International Myeloma Workshop; 2009 Feb 26-Mar 1; Washington, DC. CIG Medical Group; 2009.
115. Jakubowiak A, Richardson P, Zimmerman T, et al. Multiple Myeloma Research Consortium (MMRC) multicenter phase I results of perifosine (KRX-0410) in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma (MM). Proceedings of the International Myeloma Workshop; 2009 Feb 26-Mar 1; Washington, DC. CIG Medical Group; 2009.
116. Chang DH, Liu N, Klimek V, Hassoun H, Mazumder A, Nimer SD, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21. (Pubitemid 44061362)
117. Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001;98:210-6.
118. Tai YT, Catley LP, Mitsiades CS, Burger R, Podar K, Shringpaure R, et al. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res 2004;64:2846-52. (Pubitemid 38500624)
119. Tai YT, Li X, Tong X, Santos D, Otsuki T, Catley L, et al. Human anti- CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res 2005;65:5898-906. (Pubitemid 40911196)
120. Tai YT, Li XF, Catley L, Coffey R, Breitkreutz I, Bae J, et al. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti- CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res 2005;65:11712-20. (Pubitemid 41821732)
121. Hsi ED, Steinle R, Balasa B, Szmania S, Draksharapu A, Shum BP, et al. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma. Clin Cancer Res 2008;14:2775-84.
122. Tai YT, Soydan E, Song W, Fulciniti M, Kim K, Hong F, et al. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood 2009;113:4309-18.
123. Tai YT, Dillon M, Song W, Leiba M, Li XF, Burger P, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces
124. Lonial S, Singhal A, Jagannath S, Vij R. Phase 1b study of elotuzumab (HuLuc63) in combination with lenalidomide in relapsed multiple myeloma. Proceedings of the XII International Myeloma Workshop. 2009 Feb 26-Mar 1; Washington, DC. CIG Medical Group;2009:s20.
125. Lindemann RK, Gabrielli B, Johnstone RW. Histone-deacetylase inhibitors for the treatment of cancer. Cell Cycle 2004;3:779-88. (Pubitemid 40187911)
126. Kelly WK, Marks PA. Drug insight: Histone deacetylase inhibitors- development of the new targeted anticancer agent suberoylanilide hydroxamic acid. Nat Clin Pract Oncol 2005;2:150-7. (Pubitemid 40823166)
127. Nawrocki ST, Carew JS, Maclean KH, Courage JF, Huang P, Houghton JA, et al. Myc regulates aggresome formation, the induction of Noxa, and apoptosis in response to the combination of bortezomib and SAHA. Blood 2008;112:2917-26.
128. Mitsiades CS, Mitsiades NS, McMullan CJ, Poulaki V, Shringarpure R, Hideshima T, et al. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A 2004;101:540-5. (Pubitemid 38084672)
129. Siegel D, Weber D, Mitsiades CS, Rizvi S, Garcia-Vargas J, Howe J, et al. A phase I study of vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts)2008;112:3705.
130. Spencer A, Taylor K, Lonial S, Mateos MV, Jalaluddin M, Hazell K, et al. Panobinostat plus lenalidomide and dexamethasone phase I trial in multiple myeloma (MM). J Clin Oncol 2009;27:8542.
131. Orlowski RZ, Stewart K, Vallone M, Molineaux C, Kunkel L, Gericitano J, et al. Safety and antitumor efficacy of the proteasome inhibitor carfilzomib (PR-171) dosed for five consecutive days in hematologic malignancies: phase 1 results. Blood (ASH Annual Meeting Abstracts) 2007;110:409.
132. Alsina M, Trudel S, Vallone M, Molineaux C, Kunkel L, Goy A. Phase 1 single agent antitumor activity of twice weekly consecutive day dosing of the proteasome inhibitor carfilzomib (PR-171) in hematologic malignancies. Blood (ASH Annual Meeting Abstracts) 2007;110:411.
133. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005;8:407-19. (Pubitemid 41579835)
134. Schey SA, Fields P, Bartlett JB, Clarke IA, Ashan G, Knight RD, et al. Phase I study of an immunomodulatory thalidomide analog, CC-4047, in relapsed or refractory multiple myeloma. J Clin Oncol 2004;22:3269-76. (Pubitemid 41103682)
135. Streetly MJ, Gyertson K, Daniel Y, Zeldis JB, Kazmi M, Schey SA. Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation. Br J Haematol 2008;141:41-51. (Pubitemid 351350609)
136. Lacy MQ, Gertz MA, Hayman SR, Detweiler Short K, Dispenzieri A, Kumar S, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts) 2009;114:429.
137. Richardson P, Siegel D, Baz R, Kelley SL, Munshi NC, Sullivan D, et al. A phase 1/2 multi-center, randomized, open label dose escalation study to determine the maximum tolerated dose, safety, and efficacy of pomalidomide alone or in combination with low-dose dexamethasone in patients with relapsed and refractory multiple myeloma who have received prior treatment that includes lenalidomide and bortezomib. Blood (ASH Annual Meeting Abstracts) 2009;114:301.
138. Richardson PG, Jagannath S, Jakubowiak A, Lonial S, Raje NS, Alsina M, et al. Phase II trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood 2010;21:1257.
139. Reece DE, Piza G, Trudel S, Pantoja M, Chen C, Mikhael JR, et al. A phase I-II trial of bortezomib plus oral cyclophosphamide and prednisone for relapsed/refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2006;108:3536.
140. Schey SA, Morgan GJ, Ramasamy K, Hazel B, Ladon D, Corderoy S, et al. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study. Br J Haematol 2010;150:326-33.
141. Knop S, Gerecke C, Liebisch P, Topp MS, Platzbecker U, Sezer O, et al. Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom). Blood 2009;113:4137-43.
142. Reece DE, Masih-Khan E, Khan A, Dean S, Anglin P, Chen C, et al. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide (Revlimid(R)) (CPR) for the treatment of patients with relapsed and refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts). 2009;114:1874.